Pharming Outperforms Top-Line Estimates; Sets Aggressive FY26 Growth Outlook
Pharming Group N.V. has surpassed revenue expectations for the latest quarter, driven by strong performance in its rare disease portfolio. The company also introduced a positive fiscal year 2026 outlook, signaling confidence in the continued expansion of its primary treatments for hereditary angioedema and APDS.